Santhera is a Swiss specialty pharmaceuti- cal company focused on the development and commercialization of products for the treatment of neuromuscular and mitochondrial diseases , an area which includes many orphan and niche indications with no current therapy.

Santhera has a late-stage development pipeline in orphan indications. Catena® is Santhera's first product approved in Canada for treatment of Friedreich's Ataxia. The drug is alos under review by the EMA for marketing authorization in Leber's Hereditary Optic Neuropathy.

Santhera is currently recruiting patients for clinical studies in Duchenne Muscular Dystrophy, MELAS syndrome and Primary Progressive Multiple Sclerosis.